Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21176291 | 0.92 | ALDH1A1 (0.53) | ALDH1A1POLBKMT2AP2RX7GAA | |
| SCHEMBL21176318 | 0.82 | POLB (0.57) | ALDH1A1POLBKMT2AP2RX7GAA | |
| SCHEMBL21176163 | 0.82 | KMT2A (0.54) | ALDH1A1KMT2AP2RX7GAAMAPT | |
| SCHEMBL21176237 | 0.82 | P2RX7 (0.52) | ALDH1A1KMT2AP2RX7GAATDP1 | |
| SCHEMBL19975410 | 0.82 | P2RX7 (0.52) | ALDH1A1KMT2AP2RX7GAATDP1 | |
| SCHEMBL21176371 | 0.82 | P2RX7 (0.52) | ALDH1A1KMT2AP2RX7GAATDP1 | |
| SCHEMBL21176164 | 0.81 | ALDH1A1 (0.55) | ALDH1A1POLBKMT2AP2RX7GAA | |
| SCHEMBL21176380 | 0.80 | KMT2A (0.47) | ALDH1A1POLBKMT2AP2RX7GAA | |
| SCHEMBL21176332 | 0.79 | KMT2A (0.53) | ALDH1A1KMT2AP2RX7GAALMNA | |
| SCHEMBL21176270 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KMT2AP2RX7GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | ALDH1A1 2271/4885POLB 833/4885KMT2A 4031/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | ALDH1A1 2673/4885POLB 617/4885KMT2A 4177/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | ALDH1A1 2271/4885POLB 833/4885KMT2A 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.